Debbie Rigby rounds up the latest in research news
In a study of 3356 adults with irritable bowel syndrome (IBS) no distinct microbial signature in the the faecal and mucosa-associated microbiome was observed. Individuals presenting with low self-rated health or high BMI had lower gut microbiome richness. The authors concluded that commercial testing of stool microbiome in IBS is unlikely to help guide current therapeutic interventions.
Diet triggers symptoms in the vast majority of individuals with irritable bowel syndrome (IBS). There is growing evidence for the use of dietary therapies in IBS, with evidence for the use of traditional dietary advice, low FODMAP diet and gluten free diet. Currently there is insufficient evidence to demonstrate superiority of one dietary therapy over another.
Journal of Internal Medicine 2019;286:490–502.
In a systematic review and meta-analysis of observational studies exploring the association between DPP-4i, GLP-1ra, or SGLT2i medicines and the risk of fracture, the cumulative real-world evidence does not support an association between these classes and the risk of fracture. The use of GLP-1ra significantly reduced risk of hip fracture.
Osteoporosis International 2019;30(10):1923-40.
This meta-analysis included 16 studies indicates that tea consumption may be associated with a reduced risk of fractures. There was no dose-response relationship between tea consumption and the risk of fractures. Tea polyphenols, as one of the main components of tea, can regulate the bone metabolism of osteoblasts and osteoclasts. Also abundant elements such as fluorine, phosphorus, calcium, and manganese and vitamins C and K may modulate bone metabolism and reduce fracture risk.
Osteoporosis International 2019;30(10):1941-51